CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F17%3A73581186" target="_blank" >RIV/61989592:15110/17:73581186 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00098892:_____/17:N0000015

Výsledek na webu

<a href="http://dx.doi.org/10.1111/ejh.12902" target="_blank" >http://dx.doi.org/10.1111/ejh.12902</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/ejh.12902" target="_blank" >10.1111/ejh.12902</a>

Jazyk výsledku

angličtina

Název v původním jazyce

CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy

Popis výsledku v původním jazyce

Abstract We present a case report of a patient relapsing after anti-CD38 treatment (daratumumab). The phenotype of the disease changed during this treatment, and the myeloma clone became CD38 negative and daratumumab refractory. We expected clonal shift, however, based on immunophenotyping, cytogenetics and arrayCGH; the clone was identical as before daratumumab-based treatment with the exception of CD38 negativity. We suggest that the downregulation or loss of CD38 might be an epigenetic &quot;escape mechanism&quot; of malignant plasma cells from antibody-based treatment. The aim of our study was to point out the pitfalls of immunophenotyping and cytogenetics in both assessing the minimal residual disease and clone detection after monoclonal antibody-based therapy.

Název v anglickém jazyce

CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy

Popis výsledku anglicky

Abstract We present a case report of a patient relapsing after anti-CD38 treatment (daratumumab). The phenotype of the disease changed during this treatment, and the myeloma clone became CD38 negative and daratumumab refractory. We expected clonal shift, however, based on immunophenotyping, cytogenetics and arrayCGH; the clone was identical as before daratumumab-based treatment with the exception of CD38 negativity. We suggest that the downregulation or loss of CD38 might be an epigenetic &quot;escape mechanism&quot; of malignant plasma cells from antibody-based treatment. The aim of our study was to point out the pitfalls of immunophenotyping and cytogenetics in both assessing the minimal residual disease and clone detection after monoclonal antibody-based therapy.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Haematology

ISSN

0902-4441

e-ISSN

—

Svazek periodika

99

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

4

Strana od-do

186-189

Kód UT WoS článku

000404936400010

EID výsledku v databázi Scopus

—